CPI Breaks Ground on UK National Biologics Manufacturing Center

By Pharma News - DCAT Publisher

April 17, 2014

The Center for Process Innovation (CPI) broke ground on its National Biologics Manufacturing Center (NBMC) at its new Central Park, Darlington site in the United Kingdom. Steve Bagshaw, CEO Fujifilm Diosynth Biotechnologies, and Sandy Anderson, OBE, Chair of Tees Valley Unlimited, attended the ground-breaking ceremony.

Due for completion in 2015, the center is part of the UK government's "Strategy for UK Life Sciences" launched in 2011 to strengthen the UK's life-science sector. CPI was selected to establish and manage the new £38-million ($64-million) center.

The purpose of the NBMC is to enable the biopharmaceutical industry to capitalize on its strong research and development pipeline and make more therapies available for unmet clinical needs. CPI supports the commercialization of research by promoting collaboration with industry across the supply chain from research through to manufacture and clinic.

Source: Center for Process Innovation